Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary grade 3 or 4 malignant glioma of 1 of the following types:~  * Glioblastoma multiforme~ * Gliosarcoma~ * Anaplastic astrocytoma~ * Anaplastic oligodendroglioma~* Patients with recurrent disease whose original diagnostic pathology confirmed malignant glioma will not need re-biopsy~* Measurable recurrent or residual primary disease on contrast-enhanced MRI or CT scan~* Failed ≥ 1 prior chemotherapy regimen (with or without radiotherapy)~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Hematocrit \> 29%~* Absolute neutrophil count \> 1,500/mm\^3~* Platelets \> 125,000/mm\^3~* Serum SGOT and bilirubin \< 1.5 times upper limit of normal~* Creatinine \< 1.5 mg/dL~* Urine protein:creatinine ratio ≤ 1.0~* Blood pressure ≤ 150/100 mmHg~* No unstable angina~* No New York Heart Association class II or greater congestive heart failure~* No myocardial infarction within the past 6 months~* No stroke within the past 6 months~* No clinically significant peripheral vascular disease~* No evidence of bleeding diathesis or coagulopathy~* No significant traumatic injury within the past 28 days~PRIOR CONCURRENT THERAPY:~* At least 4 weeks must have elapsed since prior chemotherapy or radiotherapy unless there is unequivocal evidence of tumor progression~* At least 6 weeks since prior surgical resection~* No previous major surgical procedures or open biopsies within 28 days prior to study entry~* No previous minor surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to study entry~* No anticipated need for major surgical procedures during the course of the study~* No concurrent aspirin, non-steroidal anti-inflammatory drugs, or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).